Valneva Austria on Muck Rack

Valneva Austria

As seen in: The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Valneva

Contact Valneva, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil

|
By Valneva Austria, Andrea Pfeiffer, Vera Buerger, Petra Schoengrundner
| The Lancet Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Patterson, J ∙ Sammon, M ∙ Garg, M Dengue, Zika and chikungunya: emerging arboviruses in the New World West J Emerg Med. 2016; 17:671-679 2. Pan American Health Organization, World Health Organization Number of reported cases of chikungunya fever in the Americas 3. Manzoor, KN ∙ Javed, F ∙ Ejaz, M ∙ et al. The global emergence of chikungunya infection: an integrated view Rev Med Virol. 2022; 32, e2287 4.
Open in Who Shared Issue with article?

Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b study

|
By Robert McMahon, Valneva Austria, Sebastian Toepfer, Natascha Sattler
| The Lancet Verified
Research in context Evidence before this study The live-attenuated chikungunya vaccine VLA1553 (Valneva Austria, Vienna, Austria) has been approved by the US Food and Drug Administration (FDA). The vaccine is based on the La Réunion strain of the east central South African genotype of the Indian Ocean lineage, and cross-neutralises other chikungunya virus genotypes.
Open in Who Shared Issue with article?

Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial

|
By Rajeka Lazarus, Hospitals Bristol, Benedicte Querton, Valneva Austria
| The Lancet Verified
Summary Background The Valneva COVID-19 vaccine (VLA2001; Valneva Austria, Vienna, Austria) is an inactivated whole-virus, adjuvanted SARS-CoV-2 vaccine. We aimed to assess the safety and immunogenicity of primary vaccination with VLA2001 versus the ChAdOx1-S (Oxford-AstraZeneca) adenoviral-vectored vaccine.
Open in Who Shared Issue with article?
See all 3 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified